Irinotecan- vs. Oxaliplatin-Based Doublets in KRAS^G12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis.

ABSTRACT:

Background

KRAS^G12C-mutated metastatic colorectal cancer (mCRC) has recently been recognized as a distinct druggable molecular entity; however, there are limited data on its sensitivity to standard chemotherapy. In the near future, the combination of chemotherapy plus a KRAS^G12C-inhibitor might become the standard of care; however, the optimal chemotherapy backbone is unknown.

Methods

A multicentre retrospective analysis was conducted including KRAS^G12C-mutated mCRC patients treated with first-line FOLFIRI or FOLFOX +/- bevacizumab. Both unmatched and propensity-score-matched analysis (PSMA) were conducted, with PSMA controlling for: previous adjuvant chemotherapy, ECOG PS, use of bevacizumab in first line, timing of metastasis appearance, ti

SUBMITTER: Formica V 

PROVIDER: S-EPMC10252545 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature